Novartis announced successful Phase 3 trial outcomes for ianalumab, a B-cell targeting antibody showing statistically significant improvements in disease activity for Sjögren’s syndrome patients. The trials, NEPTUNUS 1 and 2, are the first global studies to demonstrate effectiveness in this systemic autoimmune disorder. The drug exhibited a favorable safety profile and is poised to become the first targeted therapy approved for this indication, marking a substantial advancement in treatment options for patients with limited therapies.